Rekah Pharmaceutical ProdXTAE:REKA -3.01%57 OCF Margin % is 6.35% as of Mar. 2026, which is 28% below its 10-year median of 8.76. GuruFocus rates XTAE:REKA with a GF Score™ of 57/100 and a GF Value™ of ₪13.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 964 Drug Manufacturers companies, Rekah Pharmaceutical Prod ranks worse than 65.87% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:REKA vs ZTS, UTHR, VTRS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod (XTAE:REKA) has a OCF Margin % of 6.35% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Rekah Pharmaceutical Prod and its competitors. This is 28% below median its historical median of 8.76. Over the past decade, Rekah Pharmaceutical Prod's OCF Margin % has ranged from 4.25 to 17.26. According to the industry distribution chart, Rekah Pharmaceutical Prod ranks #635 out of 964 companies in the Drug Manufacturers industry, placing it in the top 65.9%.
Is Rekah Pharmaceutical Prod's OCF Margin % too high?
Rekah Pharmaceutical Prod's current OCF Margin % of 6.35% is 28% below median its 10-year median of 8.76. Over the past 10 years, this metric has ranged from a low of 4.25 to a high of 17.26. The Drug Manufacturers industry median OCF Margin % is 10.04. Rekah Pharmaceutical Prod's value of 6.35% is 36.7% below this industry median. Based on the distribution chart, Rekah Pharmaceutical Prod ranks #635 out of 964 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rekah Pharmaceutical Prod ranks #635 out of 964 companies for OCF Margin %. This places Rekah Pharmaceutical Prod in the lower half of its industry. The industry median OCF Margin % is 10.04. Rekah Pharmaceutical Prod's value of 6.35% is 36.7% below this benchmark. Historically, Rekah Pharmaceutical Prod's own OCF Margin % has ranged from 4.25 to 17.26 over the past decade. While the company's 10-year median is 8.76 vs. the industry median of 10.04, Rekah Pharmaceutical Prod has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rekah Pharmaceutical Prod's current OCF Margin % of 6.35% is 36.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Rekah Pharmaceutical Prod and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rekah Pharmaceutical Prod's current OCF Margin % is 6.35%, which is 28% below median its own 10-year median of 8.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.30 — trading 21.1% below its estimated fair value. The current OCF Margin % is 6.35%, which is 28% below median its 10-year median of 8.76 and 36.7% below the Drug Manufacturers industry median of 10.04. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current OCF Margin % is 6.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪10.30 is trading 21.1% below its estimated GF Value™ of ₪13.05.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
OCF Margin %: 6.35% (28% below median its 10-year median of 8.76)
GF Value™: ₪13.05 vs. price of ₪10.30 (21.1% below fair value)
Industry Position: 36.7% below the Drug Manufacturers median (#635 of 964)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
